Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tibotec Files Once-Daily NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV

This article was originally published in The Pink Sheet Daily

Executive Summary

Studies supporting the application had a mysterious difference in outcomes. Further analysis of virologic failures is under way, says lead investigator.

You may also be interested in...



Rilpivirine Label Highlights Risk In Patients With Higher HIV Levels, Could Limit Use

Lead investigator from Phase III trials says Edurant could be viable option in about half of treatment-naïve patients, points out safety advantages.

Rilpivirine Label Highlights Risk In Patients With Higher HIV Levels, Could Limit Use

Lead investigator from Phase III trials says Edurant could be viable option in about half of treatment-naïve patients, points out safety advantages.

Gilead's Next HIV Triple-Combo Pill May Prevent Generic Erosion; Can It Prevent Infection Itself?

The company filed for FDA approval of a combination of Truvada with J&J's investigational non-nucleoside reverse transcriptase inhibitor TMC278, a regimen that could supplant Atripla.

Related Content

Topics

UsernamePublicRestriction

Register

PS070961

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel